Skip to main content
Sign In
 

Clinical Trials

Volunteer to Be Part of a Research Study


Page through all School of Medicine clinical and research trials below. There are two categories: 

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please submit your Web ad here.  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 110.
COMIRB Approved Advertisement TitleStudy GoalsEligibility CriteriaDate Posted
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 110.
Cognitive Dysfunction in Parkinson's Disease
This research study plans to use simultaneous brain scans and memory tasks to see if stimulating certain areas of the brain improves thinking and memory. This is not a treatment study
Healthy males over 50 with Parkinson's disease on stable doses of medication and have no metal in the body (dental work may be ok).
10/21/2014
EFFECTS OF TESTOSTERONE THERAPY IN YOUNG ADOLESCENTS WITH KLINEFELTER SNDROME (47.XXY)
This study will study the effects of testosterone therapy on behavior, mood, problem solving, attention span, and motor skills in adolescent males with Klinefelter syndrome in early puberty. During this period in early puberty there is a lot of variability in how and when doctors start testosterone therapy. This study will evaluate if there are benefits to starting testosterone therapy in early puberty.
Participants with Klinefelter syndrome in early puberty (around age 10-15).
10/21/2014
Join a research study that helps you lose weight and become more fit!
Seeking volunteers for a research study testing muscle lipid metabolism and diabetes risk before and after a weight loss and exercise training intervention.
Pre-diabetic Age 30-60 BMI over 30 Male or female non-smoking
10/21/2014
Managing Celiac Disease May Be More Than a Gluten-free Diet
The CeliAction Study is a clinical research study designed to evaluate the safety and effectiveness of an investigational medication for people with celiac disease.
Diagnosed with celiac disease On a gluten-free diet for at least 11 months Have experienced at least one moderate or severe celiac symptom in the past month
10/21/2014
Are you interested in losing weight?
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions (weight loss surgery or diet).
- Are 21-65 years old - Have no metal in your body - Maintained your current weight for the last 6 months - Weigh 350 pounds or less - Have a body mass index of 35 or higher (check it out at http://nhlbisupport.com/bmi/)
10/21/2014
Are you interested in a supervised weight loss intervention?
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions.
- 21-65 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for the last 6 months - Have a body mass index of 30 -40 (check it out at http://nhlbisupport.com/bmi/
10/21/2014
Are you a Parkinson's patient not requiring symptomatic treatment with drugs?
This research study explores the effects of an FDA approved drug on Parkinson's disease.
Recently diagnosed Parkinson's patients who are not taking any drugs for symptomatic relief or are willing to go off drugs for the duration of the study with neurologist approval. We are also looking for healthy control participants.
10/21/2014
The Health Influences in Puberty "HIP" study
Research study about puberty and risk for type 2 diabetes
Healthy boy between 11 and 13 years of age Healthy girl between 9 and 11 years of age
10/21/2014
Volunteers with Alzheimer’s Disease Needed for Memory Study
To examine the safety and efficacy of the study drug, Sargramostim (Leukine®), on memory in adults with Mild-to-Moderate Alzheimer’s Disease.
1. Age 55 to 85 years; 2. Should have a mild-to-moderate Alzheimer's Disease diagnosis (Mini-Mental State Examination 10-26 inclusive); 3. If on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 4. Stable on all other medications for at least 30 days prior to screen; 5. Should be fluent in English; 6. Should be physically able to participate by medical history, clinical exam and tests; 7. Should have a study partner to accompany them to scheduled visits.
10/21/2014
Healthy Hispanic Female Adults Needed
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
10/21/2014
Do you have high blood pressure?
Researchers at the University of Colorado Hospital are conducting a research study to help predict if blood pressure medications will work for you.
Subject must be between 30 and 75 years of age and have a diagnosis of uncontrolled hypertension (high blood pressure).  As part of the study, you may be eligible for free medication and free clinic visits to check your blood pressure
10/21/2014
Type 2 Diabetes and Exercise Research Study
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
10/20/2014
Volunteers with Chronic Kidney Disease needed for a Uric Acid Lowering Research Study
To understand the effect of lowering serum uric acid levels on vascular function in individuals with CKD by comparing Allopurinol therapy and a placebo.
Persons 18+ with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates  between 30-60 mL/min/1.73m2
10/20/2014
Research Study: "Anxiety Risk in Teens"
To learn more about risk factors for anxiety in adolescents with cyclic vomiting syndrome.
Adolescents 13-18 who have been diagnosed with either an anxiety disorder or cyclic vomiting syndrome
10/20/2014
Are you interested in learning about how your breast milk helps your baby grow?
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
10/20/2014
Free Family Therapy for Youth with Mood Problems
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. Must agree not to participate in family therapy with another provider for the first year.
10/20/2014
Genital Herpes?
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
18+ years of age; have developed an outbreak of genital herpes within the last 10 days.
10/20/2014
Seeking Children Ages 3 to 17 with NO History of Allergies, Eczema or Asthma
The goal of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Between the ages of 3-17 No history of allergies, eczema or asthma
10/20/2014
Induction of Labor at 39 Weeks Pregnant versus Expectant Management
Pregnant women are invited to participate in a research study which plans to learn more about whether coming to the hospital and having your labor started with medicine (ie., labor induction) at 39 weeks of pregnancy can improve the baby's health at birth when compared with waiting for labor to start on its own.
First pregnancy (no previous pregnancy beyond 20 weeks) Single baby (not twins or triplets) Planning to deliver vaginally and are at least 34 weeks pregnant Plan to deliver at University of Colorado Hospital or Denver Health Hospital
10/20/2014
Pregnant Participants Needed: A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus (GBS) Vaccine in Healthy Pregnant Women
Pregnant women are invited to participate in a research study which plans to learn about antibody (substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the GBS vaccine between 24-34 6/7 weeks of their current pregnancy.  the study will also look at antibody levels in mother's breast milk.
Healthy pregnant woman 18-40 years of age 24 0/7 through 34 6/7 weeks pregnant Planning to breastfeed for at least 90 days after delivery Plan to deliver at University of Colorado Hospital
10/20/2014
Healthy Volunteers Needed
The Department of Neurology is looking for healthy volunteers to participate in a research study examining blinking and spasms in people with Blepharospam compared to healthy controls
- Between the ages of 50-80 - Must not have any metal in your body - In good general health
10/20/2014
Healthy Volunteers Needed for a research study of drug levels in blood and hair.
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Subject is age 18 to 50 years Subject is ambulatory Subject is able to comply with directly observed dosing procedures, including use of audio-visual streaming technology Subject is able to give informed consent Subject has a minimum scalp hair length of 2 cm in the occipital region. Subject is NOT pregnant, planning to become pregnant, or currently breastfeeding Subject is low risk for HIV-1 infection Subject does NOT have any active psychiatric illness(es), social condition(s), or alcohol/drug abuse Subject does NOT have history of non-traumatic, pathologic bone fractures Subject does NOT have any medical conditions that alter red blood cell kinetics Subject does NOT have any uncontrolled medical conditions that would interfere with the study conditions Subject does NOT have contraindicated concomitant medications
10/20/2014
Overweight? Women with a BMI of 30-40 needed for a birth control research study!!
The University of Colorado School of Medicine’s Department of OB/GYN is seeking healthy volunteers for a research study of a new birth control pill.
Eligible participants must: - Have a BMI 32-40 - Be 21-35 years old - Have regular menstrual cycles
10/20/2014
Research Participants Needed
We are looking for healthy participants to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria: 1) 50-85 years of age. 2) Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 3) No neurological, vascular or cardiac problems that limit function. 4) Body mass index
10/20/2014
Do you have Parkinson's Disease?
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
10/17/2014
Do you have Atopic Dermatitis (Eczema)?
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
10/17/2014
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease.
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
10/17/2014
Are you a Non-smoking Adult between the ages of 45 and 85?
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
10/17/2014
Influenza Study
Doctors at the National Institutes of Health are conducting a research study (IRC-004) to investigate whether treating the flu decreases the amount of virus we can detect in your nose, and to understand whether the change in the amount of virus is associated with changes in your symptoms.
Volunteers may be male or female and must: -be at least 18 years old -have a history of an influenza-like illness -have an onset of illness within the past 48 hours -test positive for influenza
10/17/2014
Alterations in Lung Microbiome in Acute and Chronic HIV Infection
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
10/17/2014

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 16, items 1 to 30 of 461.
Eisenmenger Quality Enhancement Research Initiative (QuERI). Sponsor Protocol 20111728. WIRB Protocol No. 20111728
Kay, Joseph12-0926
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA. Sponsor Protocol No. WO29074. WIRB Protocol No. 20131502
Lam, Elaine13-2806
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal. Sponsor Protocol No. MDV3100-12. WIRB Protocol No. 20131280
Elias, Anthony13-2892
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM). Sponsor Protocol No. 109MS401. WIRB Protocol No. 20140071
Schreiner, Teri13-2897
A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Sponsor Protocol No. VRXP-A202. WIRB Protocol No. 20131627
Jimeno, Antonio13-2911
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure. Sponsor Protocol No. E5501-G000-311. WIRB Protocol No. 20131907
Everson, Greg13-2914
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. MDV3100-14. WIRB Protocol No. 20131112
Crawford, E13-2937
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
A Phase 1b, open-label study to assess the safety and tolerability of ONT-380 combined with capecitabine and trastuzumab, alone and in combination in HER2+ metastatic breast cancer. Sponsor Protocol No. ONT-380-005. WIRB Protocol No. 20140127
Borges, Virginia13-3000
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer. Sponsor Protocol No. XL184-210. WIRB Protocol No. 20140076
Flaig, Thomas13-3004
A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women. Sponsor Protocol No. V98_12. WIRB Protocol No. 20140324
Gibbs, Ronald13-3019
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome. Sponsor Protocol No. Neu-2566-FXS-001. WIRB Protocol No. 20132053
Tartaglia, Nicole13-3117
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected with Human Immunodeficiency Virus (HIV). Sponsor Protocol No. AI444216. WIRB Protocol No. 20140021
Campbell, Thomas13-3250
A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception. Sponsor Protocol No. 16973. WIRB Protocol No. 20140151
Tocce, Kristina13-3258
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079